Background: HLA-DR  is an MHC  (major histocompatibility complex)  class  II cell surface receptor comprised of an alpha subunit and one of several beta subunits. HLA-DR is expressed on antigen presenting cells including  B  cells,  dendritic  cells and macrophages.  HLA-DR presents peptide antigens to T helper cells at the TCR, eliciting or suppressing T cell responses that regulate the production of antibodies against the antigen.  HLA class I and II genes are highly polymorphic and studies have sampled this allelic diversity for associations to disease, revealing links between certain antigen serotypes and autoimmune diseases including rheumatoid arthritis and diabetes.

Validation: Each lot of conjugated HLA-DR antibody is quality control tested by MIBIscope™ analysis of stained tissue microarray using the appropriate positive and negative tissue field of views and are pathologist verified.

Recommended Usage: 1 uL of HLA-DR antibody per 100 uL staining volume using the MIBI™ Staining Protocol.
For optimal results, antibody should be titrated for each desired application.  Suggested starting range is 1:100.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References

• Miyadera, H. and Tokunaga, K. Associations of human leukocyte antigens with autoimmune diseases: challenges in  identifying the mechanism. Journal of Human Genetics. 2015; 60:697–702.

* Conjugate tested on human tissue.